New Gene Therapy for Sanfilippo Syndrome Type A

New Gene Therapy for Sanfilippo Syndrome Type A

New Gene Therapy for Sanfilippo Syndrome Type A

November 2026

Children’s Wisconsin first in state to offer new gene therapy for Sanfilippo syndrome type A

Children’s Wisconsin has been designated Wisconsin’s first Qualified Treatment Center (QTC) for FAYUVI™, a newly approved gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare, progressive neurodegenerative disorder.

The designation recognizes the expertise of Children’s Wisconsin’s Rare Disease Treatment Center, which provides coordinated, multidisciplinary care for children with rare genetic conditions. FAYUVI™ is a one-time IV gene therapy designed to address the underlying cause of MPS IIIA, offering the first disease-modifying treatment option for eligible patients.

This is the second gene therapy for which Children’s Wisconsin has been named a QTC, reflecting the organization’s growing expertise in advanced therapies for rare diseases. The Rare Disease Treatment Center supports patients and families before, during and after treatment, helping streamline access to specialized care and emerging therapies.

To learn more about or refer a patient to our Rare Disease Treatment Center:

Click Here

 

Back to latest news page